Drug company settles lawsuit allegations
Nebraska Attorney General says Cephalon marketed drugs to Medicaid for unapproved uses. Settlement of $2.6 million resolves Nebraska’s lawsuit allegations.
Dallas, TX(AmericanInjuryNews.com)–Cephalon, a drug company, has paid more than $2.6 million to the state of Nebraska to settle lawsuit allegations. The money is part of a $425 million national settlement with state Medicaid programs. Cephalon was sued for off-label marketing of three pharmaceutical products not approved by the U.S. Food and Drug Administration (FDA) www.fda.gov for the uses Cephalon claimed.
Cephalon has been sued nationally by multiple state Medicaid programs. The lawsuits claim Cephalon received reimbursements from state Medicaid programs for medications not approved for use by the FDA. Medicaid programs are state and federally funded. The following drugs were marketed for off-label use by Cephalon:
-Actiq a highly addictive pain killer
-Gabitril an anti-seizure drug
-Provigil a sleep disorder drug
Medical experts urge all consumers to use medications as prescribed. Consult with your doctor, pharmacist and the FDA website www.fda.gov for information regarding your medications and its intended uses. Off-label use of medications can be dangerous. If you have been injured from taking a drug you may be entitled to compensation.
AmericanInjuryNews.com by Dallas Injury Lawyer Amy K. Witherite Practice areas: Personal Injury PlaintiffAmy Witherite. Eberstein & Witherite, LLP. 3100 Monticello Avenue, Suite 500. Dallas, TX 75205 - Toll Free: (888) 407-6669 Tags: Dallas, fraud, injury, Medicaid, Settlement
Online Product Liability Personal injury lawyers - AmericanInjuryLawyers.com